| 000 | 01099 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250517035319.0 | ||
| 264 | 0 | _c20160211 | |
| 008 | 201602s 0 0 eng d | ||
| 022 | _a1532-1681 | ||
| 024 | 7 |
_a10.1016/S0268-960X(15)30006-0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNeufeld, Ellis J | |
| 245 | 0 | 0 |
_aSafety update on the use of recombinant activated factor VII in approved indications. _h[electronic resource] |
| 260 |
_bBlood reviews _cJun 2015 |
||
| 300 |
_aS34-41 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aFactor VIIa _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 650 | 0 | 4 | _aSafety |
| 700 | 1 | _aNégrier, Claude | |
| 700 | 1 | _aArkhammar, Per | |
| 700 | 1 | _aBenchikh el Fegoun, Soraya | |
| 700 | 1 | _aSimonsen, Mette Duelund | |
| 700 | 1 | _aRosholm, Anders | |
| 700 | 1 | _aSeremetis, Stephanie | |
| 773 | 0 |
_tBlood reviews _gvol. 29 Suppl 1 _gp. S34-41 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0268-960X(15)30006-0 _zAvailable from publisher's website |
| 999 |
_c24980853 _d24980853 |
||